Published in Mol Pharm on February 15, 2017
Construction of ultrasonic nanobubbles carrying CAIX polypeptides to target carcinoma cells derived from various organs. J Nanobiotechnology (2017) 0.75
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res (1995) 4.84
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation (2003) 3.45
Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation (2003) 3.15
Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation (2003) 2.67
Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation (1998) 2.57
A dynamical model for receptor-mediated cell adhesion to surfaces. Biophys J (1987) 2.49
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res (1993) 2.39
Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res (2005) 2.34
Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology (2010) 2.32
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res (2001) 2.29
Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res (2007) 2.19
Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. Circ Res (2007) 2.14
Myocardial ischemic memory imaging with molecular echocardiography. Circulation (2007) 2.13
Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation (2005) 2.04
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med (2007) 1.99
Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation (2003) 1.83
Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol (2011) 1.64
Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol Cancer Ther (2008) 1.58
Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx. Biotechnol Bioeng (2005) 1.53
Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med (2010) 1.50
Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol Imaging (2004) 1.49
Controlled and modulated release of basic fibroblast growth factor. Biomaterials (1991) 1.48
Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem (1999) 1.45
Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res (2006) 1.38
Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes (1995) 1.35
scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol (2010) 1.35
Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer (2000) 1.30
Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med (2008) 1.22
Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation (2003) 1.21
Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol (2010) 1.17
Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med (2010) 1.15
Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets (2010) 1.07
Recent advances in molecular, multimodal and theranostic ultrasound imaging. Adv Drug Deliv Rev (2013) 1.01
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia (2005) 0.99
A phospholipid-PEG2000 conjugate of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting heterodimer peptide for contrast-enhanced ultrasound imaging of angiogenesis. Bioconjug Chem (2010) 0.95
Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opin Drug Deliv (2011) 0.92
Aberrant angiogenesis: The gateway to diabetic complications. Indian J Endocrinol Metab (2012) 0.92
Albumin microbubble adherence to human coronary endothelium: implications for assessment of endothelial function using myocardial contrast echocardiography. J Am Coll Cardiol (1997) 0.89
Optimization of ultrasound contrast agents with computational models to improve selection of ligands and binding strength. Biotechnol Bioeng (2010) 0.87
Ovarian volume measurements in mice with high-resolution ultrasonography. J Ultrasound Med (2007) 0.86
Ultrasound detection of myocardial ischemic memory using an E-selectin targeting peptide amenable to human application. Mol Imaging (2014) 0.85
Vascular endothelial growth factor receptor 2-specific microbubbles for molecular ultrasound detection of prostate cancer in a rat model. Invest Radiol (2010) 0.85
Cysteine 116 participates in intermolecular bonding of the human VEGF(121) homodimer. Arch Biochem Biophys (2002) 0.80
In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Eur J Nucl Med Mol Imaging (2012) 0.79
Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice. Arch Otolaryngol Head Neck Surg (2003) 0.79
A real-time in vitro assay for studying functional characteristics of target-specific ultrasound contrast agents. Pharm Res (2004) 0.78
Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. BMC Med Imaging (2013) 0.77
Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. PLoS One (2015) 0.77
Intratumoral VEGF and FGF1 administration alters tumor growth, vascular density, oxygenation, and expression of MCP-1 and interleukins. Adv Exp Med Biol (2007) 0.76
Recombinant canstatin inhibits VEGF-A-induced lymphangiogenesis and metastasis in an oral squamous cell carcinoma SCC-VII animal model. Cancer Med (2016) 0.76